Novartis Vaccines & Diagnostics, Gmbh

Novartis Ag

Nathan Brammeier

Paul Andrew Barsanti

Weibo Wang

Paul A Renhowe

Kris Mendenhall

Megan C Phillips

Savithri Ramurthy

Sabina Pecchi

Sharadha Subramanian

David Duhl

Tinya Abrams

Annette Olga Walter

Liana Marie Lagniton

Ryan N Constantine

Kelly Wayman

Hong Yang

Mark Knapp

Yi Xia

Kenneth Walter Bair

Eric J Martin

Rama Jain

Elisa Jazan

Elizabeth J Mieuli

Rustum Boyce

Anu Sharma

Kay Huh

Vincent P Le

Zhi-Jie Ni

Yia Xia

Daniel J Poon

Keith Bruce Pfister

Cynthia Shafer

Christopher McBride

Allan S Wagman

Yasheen Zhou

Xiaodong Lin

Simon C Ng

Amy J Weiner

Rustum S Boyce

Timothy D Machajewski

Nicholas M Valiante

Barry Haskell Levine

Abran Q Costales

Alice C Rico

Teresa E Pick

William R Antonios-McCrea

Maureen McKenna

Eliza Jazan

Xia Yia

David Dibble

Jie-Kai Cheng

Brandon M Doughan

Liana Marie Lagnition

X Michael Wang

Kristin Brinner

Zhenhai Gao

Anthony Diebes

Casey Philbin

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: 

Substituted imidazole derivates

Substituted imidazole derivatives

Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Tetrahydrocarboline compounds as anticancer agents

Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.

2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula: 

Substituted imidazole compounds as KSP inhibitors

The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.

Thiosemicarbazones as anti-virals and immunopotentiators

Growing community of inventors

Walnut Creek, CA, United States of America

Nathan Brammeier